Limits...
Low CD1c + myeloid dendritic cell counts correlated with a high risk of rapid disease progression during early HIV-1 infection.

Diao Y, Geng W, Fan X, Cui H, Sun H, Jiang Y, Wang Y, Sun A, Shang H - BMC Infect. Dis. (2015)

Bottom Line: When compared with the normal controls, patients with EHI displayed significantly lower CD1c + mDC counts and IL-12 secretion and increased surface markers.CD1c + mDC counts were positively correlated with CD4+ T cell counts and inversely associated with viral loads.IL-12 secretion was only positively associated with CD4+ T cell counts.

View Article: PubMed Central - PubMed

Affiliation: Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning Province, China. cmudyy@163.com.

ABSTRACT

Background: During early HIV-1 infection (EHI), the interaction between the immune response and the virus determines disease progression. Although CD1c + myeloid dendritic cells (mDCs) can trigger the immune response, the relationship between CD1c + mDC alteration and disease progression has not yet been defined.

Methods: EHI changes in CD1c + mDC counts, surface marker (CD40, CD86, CD83) expression, and IL-12 secretion were assessed by flow cytometry in 29 patients.

Results: When compared with the normal controls, patients with EHI displayed significantly lower CD1c + mDC counts and IL-12 secretion and increased surface markers. CD1c + mDC counts were positively correlated with CD4+ T cell counts and inversely associated with viral loads. IL-12 secretion was only positively associated with CD4+ T cell counts. Rapid progressors had lower counts, CD86 expression, and IL-12 secretion of CD1c + mDCs comparing with typical progressors. Kaplan-Meier analysis and Cox regression models suggested patients with low CD1c + mDC counts (<10 cells/μL) had a 4-fold higher risk of rapid disease progression than those with high CD1c + mDC counts. However, no relationship was found between surface markers or IL-12 secretion and disease progression.

Conclusions: During EHI, patients with low CD1c + mDC counts were more likely to experience rapid disease progression than those with high CD1c + mDC counts.

No MeSH data available.


Related in: MedlinePlus

Time from baseline to CD4+ T cell count of less than 350 cells/μL or commencement of ART. a Kaplan-Meier survival plots for survival time of low and high CD1c + mDC count groups. b Kaplan-Meier survival plots for survival time of low and high IL-12 secretion groups
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4541738&req=5

Fig3: Time from baseline to CD4+ T cell count of less than 350 cells/μL or commencement of ART. a Kaplan-Meier survival plots for survival time of low and high CD1c + mDC count groups. b Kaplan-Meier survival plots for survival time of low and high IL-12 secretion groups

Mentions: Disease progression was defined according to the primary endpoint of the CD4+ T cell count of 350 cells/μL or the commencement of ART. All patients received ART at the trail endpoint. We carried out Kaplan-Meier survival analyses, and stratified according to CD1c + mDC counts (<10 cells/μL or ≥10 cells/μL) or median IL-12 level at baseline. There was a significant acceleration in clinical progression in those with lower CD1c + mDC counts (log rank × 2 = 13.63, p < 0.001) (Fig. 3a) or IL-12 level (log rank × 2 = 4.10, p = 0.043) (Fig. 3b). The median time from baseline to primary endpoint for low and high CD1c + mDC counts was 95.0 (IQR 52.0–211.5) and 821.0 (IQR 248.5-1,170.5) days, respectively; for low and high IL-12 levels, it was 77.0 (IQR 36.0–183.8) and 1,101.0 (IQR 400.0–1481.0) days, respectively (Fig. 3).Fig. 3


Low CD1c + myeloid dendritic cell counts correlated with a high risk of rapid disease progression during early HIV-1 infection.

Diao Y, Geng W, Fan X, Cui H, Sun H, Jiang Y, Wang Y, Sun A, Shang H - BMC Infect. Dis. (2015)

Time from baseline to CD4+ T cell count of less than 350 cells/μL or commencement of ART. a Kaplan-Meier survival plots for survival time of low and high CD1c + mDC count groups. b Kaplan-Meier survival plots for survival time of low and high IL-12 secretion groups
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4541738&req=5

Fig3: Time from baseline to CD4+ T cell count of less than 350 cells/μL or commencement of ART. a Kaplan-Meier survival plots for survival time of low and high CD1c + mDC count groups. b Kaplan-Meier survival plots for survival time of low and high IL-12 secretion groups
Mentions: Disease progression was defined according to the primary endpoint of the CD4+ T cell count of 350 cells/μL or the commencement of ART. All patients received ART at the trail endpoint. We carried out Kaplan-Meier survival analyses, and stratified according to CD1c + mDC counts (<10 cells/μL or ≥10 cells/μL) or median IL-12 level at baseline. There was a significant acceleration in clinical progression in those with lower CD1c + mDC counts (log rank × 2 = 13.63, p < 0.001) (Fig. 3a) or IL-12 level (log rank × 2 = 4.10, p = 0.043) (Fig. 3b). The median time from baseline to primary endpoint for low and high CD1c + mDC counts was 95.0 (IQR 52.0–211.5) and 821.0 (IQR 248.5-1,170.5) days, respectively; for low and high IL-12 levels, it was 77.0 (IQR 36.0–183.8) and 1,101.0 (IQR 400.0–1481.0) days, respectively (Fig. 3).Fig. 3

Bottom Line: When compared with the normal controls, patients with EHI displayed significantly lower CD1c + mDC counts and IL-12 secretion and increased surface markers.CD1c + mDC counts were positively correlated with CD4+ T cell counts and inversely associated with viral loads.IL-12 secretion was only positively associated with CD4+ T cell counts.

View Article: PubMed Central - PubMed

Affiliation: Department of Laboratory Medicine, The First Affiliated Hospital, China Medical University, Shenyang, Liaoning Province, China. cmudyy@163.com.

ABSTRACT

Background: During early HIV-1 infection (EHI), the interaction between the immune response and the virus determines disease progression. Although CD1c + myeloid dendritic cells (mDCs) can trigger the immune response, the relationship between CD1c + mDC alteration and disease progression has not yet been defined.

Methods: EHI changes in CD1c + mDC counts, surface marker (CD40, CD86, CD83) expression, and IL-12 secretion were assessed by flow cytometry in 29 patients.

Results: When compared with the normal controls, patients with EHI displayed significantly lower CD1c + mDC counts and IL-12 secretion and increased surface markers. CD1c + mDC counts were positively correlated with CD4+ T cell counts and inversely associated with viral loads. IL-12 secretion was only positively associated with CD4+ T cell counts. Rapid progressors had lower counts, CD86 expression, and IL-12 secretion of CD1c + mDCs comparing with typical progressors. Kaplan-Meier analysis and Cox regression models suggested patients with low CD1c + mDC counts (<10 cells/μL) had a 4-fold higher risk of rapid disease progression than those with high CD1c + mDC counts. However, no relationship was found between surface markers or IL-12 secretion and disease progression.

Conclusions: During EHI, patients with low CD1c + mDC counts were more likely to experience rapid disease progression than those with high CD1c + mDC counts.

No MeSH data available.


Related in: MedlinePlus